Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis

Mehta, Neil; Li, Andraia R.; Nguyen, Shaun A.; Kaczmar, John M.; Neskey, David M.; Day, Terry A.

doi:10.1007/s11523-021-00844-z

Cited by 3 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…which were similar but numerically lower than that from our study. 24 Consistent with our results, this study also showed that patients with locoregional and distant metastatic disease had comparable ORR during treatment. However, their study failed to assess the relationship between primary lesion, PD-L1 expression, and immune status and conducted this assessment using combined positive score.…”

Section: Discussionsupporting

confidence: 92%

“…conducted a systematic review and meta‐analysis including six prospective clinical trials. The pooled analysis of 392 patients also demonstrated that CPIs conferred ORR of 42.43% (95% CI: 37.53%–47.45%) and DCR of 58.05% (95% CI 53.04%–62.95%), which were similar but numerically lower than that from our study 24 . Consistent with our results, this study also showed that patients with locoregional and distant metastatic disease had comparable ORR during treatment.…”

Section: Discussionsupporting

confidence: 89%

“…Thus, a review of their findings is needed. A previous systematic review and meta‐analysis confirmed the efficacy and safety of CPI in for advanced and recurrent/metastatic CSCC 24 . However, this study failed to conduct further analysis due to limited references included.…”

Section: Introductionmentioning

confidence: 74%

“…A previous systematic review and meta‐analysis confirmed the efficacy and safety of CPI in for advanced and recurrent/metastatic CSCC. 24 However, this study failed to conduct further analysis due to limited references included. In this study, we sought to evaluate the efficacy and safety of CPI in advanced CSCC patients by conducting a systemic review to provide a more evidence‐based evaluation effectiveness of this treatment approach.…”

Section: Introductionmentioning

confidence: 95%

See 3 more Smart Citations

Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta‐analysis

Zhang

Zhong

Chen

2022

Skin Research and Technology

View full text Add to dashboard Cite

Background To evaluate the immune checkpoint inhibitors (CPI) for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC). Materials and methods A meta‐analysis was conducted, and the efficacy and safety of CPI were assessed. Results A total of 13 studies with 980 patients were included. The pooled objective response rate (ORR) and disease control rate were 47.2% and 64.4%, separately. In addition, patients with primary tumor located in head and neck (odds ratio [OR]: 0.374, 95% confidence interval [CI]: 0.219–0.640, p < 0.001) and positive expression of programmed death ligand 1 (OR: 0.364, 95% CI: 0.158–0.842, P = 0.018) had superior ORR during CPI treatment. The incidence of progression free survival at 6 and 12 months was 59.3% and 52.8%, and 80.6% and 76.4% for overall survival. As for safety, the overall incidence of adverse events with all grades and 3–4 grade was 76.9% and 20.2%. Conclusions Our systematic review confirmed the satisfying efficacy and acceptable toxicity of CPI for advanced CSCC.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 74%

Section: Introductionmentioning

confidence: 95%

See 2 more Smart Citations

Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta‐analysis

Zhang

Zhong

Chen

2022

Skin Research and Technology

View full text Add to dashboard Cite

show abstract

“…9 A recent meta-analysis confirmed similar tolerability between trial and 'real-world' data. 10 The limitations of our study are that it is retrospective, is a small series and has no central response assessment. In spite of this, as it was a NPS, patients needed to fulfil eligibility criteria to enrol, and there was monitoring of TRAEs.…”

mentioning

confidence: 95%

Cemiplimab in advanced cutaneous squamous cell carcinoma: the UK experience from the Named Patient Scheme

Challapalli

Watkins

Cogill

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Real-world data on tolerability and clinical response of cemiplimab in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre cohort study from the Netherlands

Rohaan,

Duizer,

Devriese

et al. 2023

EJC Skin Cancer

View full text Add to dashboard Cite

Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis

Cited by 3 publications

References 38 publications

Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta‐analysis

Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta‐analysis

Cemiplimab in advanced cutaneous squamous cell carcinoma: the UK experience from the Named Patient Scheme

Real-world data on tolerability and clinical response of cemiplimab in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre cohort study from the Netherlands

Contact Info

Product

Resources

About